Mani T. Valarmathi

Religen Inc.

Mani T. Valarmathi is currently the Director of Research and Development at Religen Inc., a life science company in Pennsylvania, USA. He began his scientific career as a cancer geneticist, but soon became captivated by the emerging and translational fields of stem cell biology, tissue engineering, and regenerative medicine. After obtaining a bachelor’s degree in Chemistry from the University of Madras, Chennai, Tamil Nadu, India, he obtained an MBBS in Medicine and Surgery and an MD in Pathology from the same university, as well as a Ph.D. in Medical Biotechnology from All-India Institute of Medical Sciences, New Delhi, India. Over the past two decades, he has had extensive experience in research on various types of stem cells, and his research work has been focused on creating bioengineered human 3D vascularized tissue constructs for implantation purposes. At present, much of his research is directed toward developing innovative molecular genetic testing for precision and genetic medicine. He is a member of many prestigious national and international professional societies and scientific organizations, including the International Society for Stem Cell Research (ISSCR), Tissue Engineering and Regenerative Medicine International Society (TERMIS), American Association for Cancer Research (AACR), American Society for Investigative Pathology (ASIP), American Society for Clinical Pathology (ASCP), American Chemical Society (ACS), European Society of Cardiology (ESC), International Society for Heart Research (ISHR), American Society of Gene & Cell Therapy (ASGCT), and American Heart Association (AHA).

Mani T. Valarmathi

5books edited

4chapters authored

Latest work with IntechOpen by Mani T. Valarmathi

Mutations in the BRCA1/2 genes are the most common cause of hereditary breast and ovarian cancer (HBOC), and HBOC is an autosomal dominant cancer predisposition syndrome. Individuals with HBOC have a high risk for breast and ovarian cancers and a moderate risk for other cancers, such as prostate, pancreatic, melanoma, and fallopian tube cancers. The goal of screening individuals at high risk of familial cancer is either prevention (such as a change in lifestyle or diet) or early detection of cancer. The identification of BRCA mutation carriers is important, since increased surveillance, drug therapy, and prophylactic surgery can reduce cancer-related morbidity and mortality. In recent years, there has been substantial development in BRCA-associated hereditary breast and/or breast-ovarian cancer research and its clinical applications. In this context, this book consolidates the recent advances in BRCA-related cancer biology and therapeutics, covering a wide spectrum of interrelated topics. Chapters cover a wide range of topics, such as BRCA discovery, BRCA structure and function, BRCA-associated cancers, BRCA genetic testing and counselling, and more. This book is a valuable resource not only for medical and allied health students but also for researchers, clinical and nurse geneticists, genetic counselors, and physician assistants.

Go to the book